This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción GRNA
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de GreenLight Biosciences Holdings
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$5.90 |
| 52 Week Low | US$0.18 |
| Beta | 1.44 |
| 1 Month Change | 3.20% |
| 3 Month Change | -6.08% |
| 1 Year Change | -85.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.94% |
Noticias y actualizaciones recientes
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Rentabilidad de los accionistas
| GRNA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 0.4% | 0.1% | 2.2% |
| 1Y | -85.2% | -1.0% | 22.8% |
Rentabilidad vs. Industria: GRNA underperformed the US Biotechs industry which returned 5.4% over the past year.
Rentabilidad vs. Mercado: GRNA underperformed the US Market which returned 13% over the past year.
Volatilidad de los precios
| GRNA volatility | |
|---|---|
| GRNA Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: GRNA's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: GRNA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | n/a | Andrey Zarur | greenlightbiosciences.com |
Resumen de fundamentos de GreenLight Biosciences Holdings
| Estadísticas fundamentales de GRNA | |
|---|---|
| Capitalización bursátil | US$45.43m |
| Beneficios(TTM) | -US$157.32m |
| Ingresos (TTM) | US$10.34m |
4.4x
Ratio precio-ventas (PS)-0.3x
Ratio precio-beneficio (PE)¿Está GRNA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de GRNA | |
|---|---|
| Ingresos | US$10.34m |
| Coste de los ingresos | US$129.70m |
| Beneficio bruto | -US$119.35m |
| Otros gastos | US$37.96m |
| Beneficios | -US$157.32m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.04 |
| Margen bruto | -1,153.96% |
| Margen de beneficio neto | -1,521.00% |
| Ratio deuda/patrimonio | 111.6% |
¿Cómo se ha desempeñado GRNA a largo plazo?
Ver rendimiento histórico y comparativa